

INNOVATION IN EYE CARE INSPIRED BY PATIENTS

Oyster Point is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies. We are focused within ophthalmology therapies for the anterior segment of the eye, including ocular surface diseases.



OUR SCIENCE

We believe it is our responsibility to transform ocular surface health with cutting-edge science.

We are hopeful that our **research and development** efforts may help enhance the lives of patients living with ocular surface diseases. Our research focus includes pharmaceutical approaches to treat ocular surface diseases, including cholinergic science, gene therapy, and bacteriophage therapy.

We are excited to pursue the evaluation of the benefits of taking advantage of the body's neurological system to transform the way we think about **ocular surface health**.



OUR HISTORY

Oyster Point was founded in 2015 after it was spun out from Oculeve® as a separate entity to develop pharmaceutical opportunities in the ocular health space.

We are now focused on building out our commercial organization and expanding our sales force with plans to grow the company to over 300 employees in 2021.

2015

2019

2021

In October 2019, we announced our initial public offering and shares began trading on The Nasdaq Global Select Market under the symbol "OYST."

OUR PEOPLE

Over 100 years of experience dedicated to eye care innovation.

Unparalleled expertise in ophthalmology — our team of professionals has a passion for science and an unwavering dedication to revolutionize ocular surface innovation.

Oyster Point is powered by a team of experts with a combined 200+ years of experience in the biopharmaceutical space. Oyster Point is unwaveringly focused and dedicated to one common goal –transforming ocular surface disease to change the lives of patients.



JEFFREY NAU, PHD, MMS
President and Chief Executive Officer

Built his career on developing novel, innovative therapies for diseases of the eye with roles at Ophthotech, Genentech, Acuity and NeoVista.



ERIC CARLSON, PHD
Chief Scientific Officer

Eric has over 20 years of experience in ophthalmology with discovery and development leadership roles at Akorn Pharmaceuticals, Aerie Pharmaceuticals, Novartis and Alcon.



DANIEL LOCHNER, MBA
Chief Financial Officer

Daniel has nearly 15 years of experience in healthcare investing focused on a variety of therapeutic categories, including ophthalmology.



MARIAN MACSAI, MD
Chief Medical Officer, Medical Affairs

Over 30 years of ophthalmology experience and continues to hold a variety of external leadership positions such as, Clinical Professor of Ophthalmology University of Chicago Pritzker School of Medicine.



JOHN SNISARENKO, MBA
Chief Commercial Officer

Over 30 years of commercial experience in the pharmaceutical industry, including major ophthalmology businesses with previous roles at Shire, Novartis and Genentech.



MIKE CAMPBELL
Vice President & Head of Sales and Commercial Operations

Over 28 years of pharma experience in commercialization, sales, marketing, market access and operations with previous roles at Shire, Novartis and Genentech.



DAWN PRUITT KOFFLER, MBA
Vice President of Marketing

Seasoned professional with nearly 20 years of experience in pharmaceutical sales and marketing with previous roles at Allergan Eye Care and Johnson and Johnson.



MATT MAGUIRE
Vice President, Market Access, Trade & Patient Services

Market access professional with over 20 years of pharmaceutical/biotech experience with previous roles at Shire, Novartis and Genentech.